Twinbeech Capital LP Kodiak Sciences Inc. Transaction History

Twinbeech Capital LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.57 - $12.5 $250,514 - $413,662	33,093 New	33,093 $256,000
Q1 2022 May 16, 2022	SELL	$7.09 - $89.45 $22,298 - $281,320	-3,145 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$80.85 - $128.49 $254,273 - $404,101	3,145 New	3,145 $267,000
Q3 2020 Nov 16, 2020	SELL	$45.05 - $59.27 $407,206 - $535,741	-9,039 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$42.74 - $66.25 $386,326 - $598,833	9,039 New	9,039 $489,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Twinbeech Capital LP, based on Form 13F filings with the SEC.

Stay updated on Twinbeech Capital LP with notifications on news.